Surgery After Relapse in Stage I Nonseminomatous Testicular Cancer

Daugaard, Gedske; Gundgaard, Maria Gry; Mortensen, Mette Saksø; Agerbæk, Mads; Holm, Niels V.; Rørth, Mikael; Maase, Hans von der; Christensen, Ib Jarle; Lauritsen, Jakob

doi:10.1200/jco.2014.60.2177

Cited by 5 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with TGCTs have a good prognosis; stage I patients who receive only surgical resection have an 85.5-95% 5 year survival rate, and even patients with metastasis still have a cure rate of ∼80%, because TGCTs are sensitive to radiotherapy and chemotherapy, such as cisplatin and other cytostatic agents (1,(4)(5)(6). Previous studies have shown that advanced TNM stage, high serum tumor marker level (7-9), non-seminoma or predominantly embryonal carcinoma histology (10), lymph vascular invasion (11)(12)(13), rete testis invasion (14,15), and large tumor size (15,16) are risk factors of poor prognosis or relapse. However, based on conventional clinical or pathological characteristics, the prediction of recurrence is still not sufficiently accurate and remains controversial in TGCTs (1,15), especially in stage I patients who are subjected to surveillance after radical orchiectomy (5).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors

et al. 2020

View full text Add to dashboard Cite

Background: Testicular germ cell tumors (TGCTs) are commonly diagnosed tumors in young men. However, a satisfactory approach to predict relapse of stage I TGCTs is still lacking. Therefore, this study aimed to develop a robust risk score model for stage I TGCTs. Method: RNA-sequence data of stage I TGCTs and normal testis samples were downloaded and analyzed to identify different expression genes. Gene-based prognostic model was constructed in The Cancer Genome Atlas (TCGA) using least absolute shrinkage and selection operator (LASSO) regression analysis and validated in GSE99420 dataset. Potential biological functions of the genes in prognostic model were determined via Gene Set Enrichment Analysis (GSEA) between high-risk and low-risk patients. Results: A total of 9,391 differentially expressed genes and 84 prognosis-related genes were identified. An eight-gene-based risk score model was constructed to divide patients into high or low risk of relapse. The low-risk patients had a significantly better relapse-free survival (RFS) than high-risk patients in both training and validation cohorts (HR = 0.129, 95% CI = 0.059-0.284, P < 0.001; HR = 0.277, 95% CI = 0.116-0.661, P = 0.004, respectively). The area under the receiver operating characteristic curve (AUC) values at 5 years was 0.805 and 0.724 in the training and validation cohorts, respectively. Functional enrichment analyses showed that DNA replication, ribosome, cell cycle, and TGF-beta signaling pathway may contribute to the relapse process. Conclusion: In summary, our analysis provided a novel eight-gene signature that could predict RFS in stage I TGCT patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This may be secondary to the frequent presence of tumour‐smearing artefact in seminoma, making identification of genuine LVI challenging (Figure ). For NSGCTs, LVI has been shown in multiple studies to be a powerful predictor of metastatic disease and recurrence . If LVI is present in a mixed or combined germ cell tumour, it is good practice to state which subtype of tumour is showing the LVI, as this may alter clinical management if it is an embryonal carcinoma component showing LVI versus classic seminoma.…”

Section: Methodsmentioning

confidence: 99%

“…For NSGCTs, LVI has been shown in multiple studies to be a powerful predictor of metastatic disease and recurrence. 25,27,[46][47][48][49][50][51] If LVI is present in a mixed or combined germ cell tumour, it is good practice to state which subtype of tumour is showing the LVI, as this may alter clinical management if it is an embryonal carcinoma component showing LVI versus classic seminoma.…”

Section: Y M P H O V a S C U L A R I N V A S I O N ( R E Q U I R E D )mentioning

confidence: 99%

Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting

et al. 2018

View full text Add to dashboard Cite

We here describe the development of an evidence‐based cancer dataset by an International Collaboration on Cancer Reporting expert panel for the reporting of primary testicular neoplasia, and present the ‘required’ and ‘recommended’ elements to be included in the pathology report, as well as a commentary. This dataset encompasses the updated 2016 World Health Organisation classification of urological tumours, the results of an International Society of Urological Pathology consultation, and also staging with our preferred method: the American Joint Committee on Cancer version 8. Implementation of this dataset will facilitate consistent and accurate data collection between different cohorts, facilitate research, and hopefully result in improved patient management.

show abstract

A model based on tumor-infiltrating immune cells for predicting the relapse rates of patients with testicular germ cell tumors

Wang

Liu

et al. 2020

International Immunopharmacology

View full text Add to dashboard Cite

Surgery After Relapse in Stage I Nonseminomatous Testicular Cancer

Cited by 5 publications

References 3 publications

Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors

Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors

Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting

A model based on tumor-infiltrating immune cells for predicting the relapse rates of patients with testicular germ cell tumors

Contact Info

Product

Resources

About